| Transpharm Clinical Consulting Ltd |
| Registered number: |
11304280 |
| Balance Sheet |
| as at 30 April 2026 |
|
| Notes |
|
|
2026 |
|
|
2025 |
| £ |
£ |
| Fixed assets |
| Tangible assets |
3 |
|
|
- |
|
|
752 |
|
| Current assets |
| Debtors |
4 |
|
413 |
|
|
8,951 |
| Cash at bank and in hand |
|
|
144,955 |
|
|
162,717 |
|
|
|
145,368 |
|
|
171,668 |
|
| Creditors: amounts falling due within one year |
5 |
|
(18,081) |
|
|
(12,676) |
|
| Net current assets |
|
|
|
127,287 |
|
|
158,992 |
|
| Total assets less current liabilities |
|
|
|
127,287 |
|
|
159,744 |
|
|
| Provisions for liabilities |
|
|
|
- |
|
|
(143) |
|
|
| Net assets |
|
|
|
127,287 |
|
|
159,601 |
|
|
|
|
|
|
|
|
| Capital and reserves |
| Called up share capital |
|
|
|
1 |
|
|
1 |
| Profit and loss account |
|
|
|
127,286 |
|
|
159,600 |
|
| Shareholder's funds |
|
|
|
127,287 |
|
|
159,601 |
|
|
|
|
|
|
|
|
| The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The member has not required the company to obtain an audit in accordance with section 476 of the Act. |
| The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| Dr M. Taylor |
| Director |
| Approved by the board on 22 June 2026 |
|
| Transpharm Clinical Consulting Ltd |
| Notes to the Accounts |
| for the year ended 30 April 2026 |
|
|
| 1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Turnover |
|
Turnover is measured at the fair value of the consideration received or receivable, net of discounts. |
|
|
Tangible fixed assets |
|
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: |
|
|
Fixtures, fittings, tools and equipment |
over 3 years |
|
|
Debtors |
|
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. |
|
|
Creditors |
|
Short term creditors are measured at transaction price (which is usually the invoice price). |
|
|
Taxation |
|
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Current and deferred tax liabilities are not discounted. |
|
|
| 2 |
Employees |
2026 |
|
2025 |
| Number |
Number |
|
|
Average number of persons employed by the company |
0 |
|
0 |
|
|
|
|
|
|
|
|
|
|
| 3 |
Tangible fixed assets |
|
|
|
|
|
|
|
|
Plant and machinery etc |
| £ |
|
Cost |
|
At 1 May 2025 |
2,255 |
|
Disposals |
(2,255) |
|
At 30 April 2026 |
- |
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
At 1 May 2025 |
1,503 |
|
Charge for the year |
752 |
|
On disposals |
(2,255) |
|
At 30 April 2026 |
- |
|
|
|
|
|
|
|
|
|
|
Net book value |
|
At 30 April 2026 |
- |
|
At 30 April 2025 |
752 |
|
|
| 4 |
Debtors |
2026 |
|
2025 |
| £ |
£ |
|
|
Trade debtors |
- |
|
8,860 |
|
Other debtors |
413 |
|
91 |
|
|
|
|
|
|
413 |
|
8,951 |
|
|
|
|
|
|
|
|
|
|
| 5 |
Creditors: amounts falling due within one year |
2026 |
|
2025 |
| £ |
£ |
|
|
Taxation and social security costs |
15,916 |
|
9,992 |
|
Other creditors |
2,165 |
|
2,684 |
|
|
|
|
|
|
18,081 |
|
12,676 |
|
|
|
|
|
|
|
|
|
|
| 6 |
Other information |
|
|
Transpharm Clinical Consulting Ltd is a private company limited by shares and incorporated in England. Its registered office is: |
|
International House |
|
Cornhill |
|
London |
|
EC3V 3NG |